Walleye Capital
ALXN

Walleye Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,600
Closed -$1.4M – 1106
2020
Q1 		$1.4M Sell
15,600
-27,200
-64% -$2.67M 0.31% 87
2019
Q4 		$4.63M Buy
42,800
+42,200
+7,033% +$4.51M 0.3% 48
2019
Q3 		$59K Hold
600
– – ﹤0.01% 1574
2019
Q2 		$79K Sell
600
-3,700
-86% -$477K 0.01% 1288
2019
Q1 		$581K Buy
+4,300
New +$535K 0.1% 332

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Walleye Capital's ALXN Position: Q3 2021 in Review

Walleye Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 66,350 shares — an estimated $12.2K sold.

Walleye Capital first reported a position in ALXN in Q3 2018 and held it in 10 quarters. The position peaked at $1.99M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Walleye Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Walleye Capital sold 66,350 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.2K.
  • Walleye Capital first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Walleye Capital's Alexion Pharmaceuticals position peaked at $1.99M in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Capital's 13F filing for Q3 2021, filed 15 Nov 2021.